Overview

Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. A key partnership with Boehringer Ingelheim highlights the potential of their digital therapeutics, particularly in treating conditions like schizophrenia. The goal of Click Therapeutics is to provide effective digital solutions for patients with unmet medical needs, continuously improving their applications using real-world evidence.

Simplify's Take

What believers are saying

• FDA clearance of Rejoyn™ boosts their presence in mental health treatment.
• Acquisition of Better Therapeutics expands their portfolio into cardiometabolic diseases.
• Partnership with Otsuka enhances commercialization and patient engagement for Rejoyn™.

What critics are saying

• Increased competition from companies like Pear Therapeutics in digital therapeutics.
• Potential challenges in securing reimbursement from hesitant insurers.
• Integration challenges from Better Therapeutics acquisition may impact productivity.

What makes Click Therapeutics unique

• Click Therapeutics develops software as medical treatments for unmet medical needs.
• Their Clickometrics® platform personalizes user experience to optimize engagement and outcomes.
• Partnership with Boehringer Ingelheim highlights their collaborative approach in digital therapeutics.

Help us improve and share your feedback! Did you find this helpful?

YesNo